Squarepoint
ZVRA icon

Squarepoint’s Zevra Therapeutics ZVRA Stock Holding History

Squarepoint’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-182,864
Closed -$1.7M – 5076
2026
Q1 		$1.7M Sell
182,864
-134,202
-42% -$1.21M ﹤0.01% 2312
2025
Q4 		$2.84M Buy
317,066
+48,989
+18% +$463K ﹤0.01% 1835
2025
Q3 		$2.55M Buy
+268,077
New +$2.69M ﹤0.01% 1904
2025
Q2 		– Sell
-68,050
Closed -$510K – 5166
2025
Q1 		$510K Buy
68,050
+51,516
+312% +$409K ﹤0.01% 3285
2024
Q4 		$138K Buy
16,534
+4,384
+36% +$37.4K ﹤0.01% 4606
2024
Q3 		$84.3K Buy
+12,150
New +$82.5K ﹤0.01% 3905
2024
Q2 		– Sell
-22,332
Closed -$130K – 4742
2024
Q1 		$130K Sell
22,332
-776
-3% -$4.77K ﹤0.01% 3737
2023
Q4 		$151K Buy
23,108
+3,930
+20% +$18.4K ﹤0.01% 3675
2023
Q3 		$92.4K Buy
19,178
+467
+2% +$2.33K ﹤0.01% 3569
2023
Q2 		$95.4K Sell
18,711
-1,546
-8% -$8.33K ﹤0.01% 3371
2023
Q1 		$111K Buy
+20,257
New +$107K ﹤0.01% 2952
2022
Q1 		– Sell
-10,202
Closed -$89K – 3636
2021
Q4 		$89K Buy
+10,202
New +$91K ﹤0.01% 2945
2021
Q2 		– Sell
-26,206
Closed -$241K – 3770
2021
Q1 		$241K Buy
+26,206
New +$229K ﹤0.01% 2572

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squarepoint's ZVRA Position: Q2 2026 in Review

Squarepoint sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 182,864 shares — an estimated $1.7M sold.

Squarepoint first reported a position in ZVRA in Q1 2021 and held it in 13 quarters. The position peaked at $2.84M in Q4 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Squarepoint reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 182,864 Zevra Therapeutics shares in Q2 2026, an estimated $1.7M.
  • Squarepoint first reported a position in Zevra Therapeutics in Q1 2021 and held it in 13 quarters.
  • Squarepoint's Zevra Therapeutics position peaked at $2.84M in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.